Royal Bank of Canada’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-126,695
| Closed | -$7.58M | – | 7319 |
|
|
2019
Q4 | $7.58M | Buy |
126,695
+126,588
| +118,307% | +$4.75M | ﹤0.01% | 1831 |
|
|
2019
Q3 | $3K | Buy |
107
+13
| +14% | +$444 | ﹤0.01% | 6253 |
|
|
2019
Q2 | $4K | Buy |
94
+43
| +84% | +$1.65K | ﹤0.01% | 6443 |
|
|
2019
Q1 | $2K | Hold |
51
| – | – | ﹤0.01% | 6593 |
|
|
2018
Q4 | $1K | Sell |
51
-814
| -94% | -$21K | ﹤0.01% | 6664 |
|
|
2018
Q3 | $34K | Buy |
865
+700
| +424% | +$26.1K | ﹤0.01% | 5424 |
|
|
2018
Q2 | $6K | Buy |
165
+112
| +211% | +$4.15K | ﹤0.01% | 6016 |
|
|
2018
Q1 | $2K | Sell |
53
-16
| -23% | -$542 | ﹤0.01% | 6156 |
|
|
2017
Q4 | $3K | Sell |
69
-1,350
| -95% | -$37.1K | ﹤0.01% | 6233 |
|
|
2017
Q3 | $40K | Buy |
1,419
+1,365
| +2,528% | +$29.6K | ﹤0.01% | 5556 |
|
|
2017
Q2 | $1K | Sell |
54
-214
| -80% | -$3.42K | ﹤0.01% | 6483 |
|
|
2017
Q1 | $5K | Sell |
268
-2
| -0.7% | -$32 | ﹤0.01% | 6239 |
|
|
2016
Q4 | $5K | Buy |
270
+170
| +170% | +$2.94K | ﹤0.01% | 6317 |
|
|
2016
Q3 | $2K | Buy |
+100
| New | +$1.52K | ﹤0.01% | 6224 |
|
Royal Bank of Canada's BOLD Position: Q1 2020 in Review
Royal Bank of Canada sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 126,695 shares — an estimated $7.58M sold.
Royal Bank of Canada first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $7.58M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- Royal Bank of Canada reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- Royal Bank of Canada sold 126,695 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $7.58M.
- Royal Bank of Canada first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
- Royal Bank of Canada's Audentes Therapeutics, Inc position peaked at $7.58M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on Royal Bank of Canada's 13F filing for Q1 2020, filed 15 May 2020.